# Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

> **NCT05393284** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Valo Health, Inc.** · enrollment: 114 (actual)

## Conditions studied

- Non-proliferative Diabetic Retinopathy
- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** OPL-0401 Dose 1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05393284
- **Lead sponsor:** Valo Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-16
- **Primary completion:** 2024-08
- **Final completion:** 2024-08
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05393284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05393284, "Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05393284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*